|
|||||
|
|
MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV |
|
| Authors: | Anilkumar G. Nair Qingbei Zeng Oleg Selyutin Stuart B. Rosenblum Yueheng Jiang De-Yi Yang Kerry Keertikar Guowei Zhou Michael Dwyer Seong Heon Kim Bandarpalle Shankar Wensheng Yu Ling Tong Lei Chen Robert Mazzola John Caldwell Haiqun Tang Sony Agrawal Joseph A. Kozlowski |
| Affiliation: | Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA |
| Abstract: | HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination regimen. Herein, we describe the discovery and characterization of silyl proline-containing HCV NS5A inhibitor MK-8325 with good pan-genotype activity and acceptable pharmacokinetic properties. |
| Keywords: | HCV NS5A Antiviral Silyl proline |
| 本文献已被 ScienceDirect 等数据库收录！ | |